Dr. Ha­bil Kho­raki­wala,

Founder Chair­man of Wockhardt

Business Sphere - - CONTENTS - By Our Cor­re­spon­dent

“Wockhardt Group, a re­search based Global Phar­ma­ceu­ti­cal and Biotech ma­jor, sets up its first fa­cil­ity in Mid­dle East for man­u­fac­tur­ing of NCEs (New Chem­i­cal En­ti­ties) cater­ing to the global mar­kets through its Dubai arm of its sub­sidiary Wockhardt Bio AG.” With an aim to grow and fur­ther es­tab­lish their in­ter­na­tional pres­ence in phar­ma­ceu­ti­cal man­u­fac­tur­ing, Wockhardt in­au­gu­rated a ‘state-ofthe-art’ man­u­fac­tur­ing fa­cil­ity for the pro­duc­tion and pack­ag­ing of ster­ile dry pow­der in­jec­tion in Dubai. On ap­proval of the new drug by US FDA, this man­u­fac­tur­ing fa­cil­ity will be com­mis­sioned for com­mer­cial pro­duc­tion. Dur­ing the in­au­gu­ra­tion of the new fa­cil­ity, Dr. Ha­bil Kho­raki­wala, Founder Chair­man of Wockhardt said, “Wockhardt is poised for a quan­tum leap into the fu­ture. It is a fu­ture of dy­namic changes, ex­cit­ing pos­si­bil­i­ties and end­less po­ten­tial to fur­ther its goal of ‘Life Wins’ and Wockhardt is com­mit­ted to shap­ing this fu­ture. With Wockhardt’s com­mit­ment to R&D, we have 5 break­through New Chem­i­cal En­ti­ties (NCEs) that have been ac­corded Qual­i­fied In­fec­tious Dis­ease Prod­uct (QIDP) sta­tus by US FDA. With the new fa­cil­ity in Mid­dle East, we aim to fo­cus on our com­mit­ment in de­vel­op­ing NCEs to fight the health is­sues faced.” An­timi­cro­bial re­sis­tance (AMR) - the abil­ity of in­fec­tions to re­sist an­tibi­otics to work against it is in­creas­ingly rec­og­nized as grow­ing global health prob­lem. In­fec­tions caused by an­timi­cro­bial re­sis­tant strains of bac­te­ria-also called “su­per­bugs” are un­likely to re­spond to stan­dard treat­ments re­sult­ing in pro­longed ill­ness and a greater risk to health, and se­verely im­pact­ing clin­i­cal out­comes, lead­ing to fur­ther higher health­care costs due to con­sump­tion of health­care re­sources. Wockhardt cur­rently has 5 novel an­tibi­otic drugs in ad­vanced stages of global clin­i­cal devel­op­ment which will be ef­fec­tive against these “su­per­bugs” threats iden­ti­fied by the Cen­ter of Dis­ease Con­trol, USA. Con­sid­er­ing the strate­gic im­por­tance of these an­tibi­otics, the US FDA has granted Qual­i­fied In­fec­tious Dis­ease Pro­gram (QIDP) sta­tus to the 5 novel an­tibi­otic drugs. “Wockhardt has ded­i­cated sig­nif­i­cant re­sources for the dis­cov­ery and devel­op­ment of novel an­tibi­otics. These novel drugs in ad­vanced stages of global devel­op­ment are a cul­mi­na­tion of 20 years of ded­i­cated and fo­cused re­search in the an­tibi­otics ther­apy seg­ment with an aim to im­prove the qual­ity of life”, said Dr. Mur­taza Kho­raki­wala, Man­ag­ing Di­rec­tor of Wockhardt. “The fa­cil­ity will work on the ex­hibit batches and will be of­fered for in­spec­tion by the reg­u­la­tors at an ap­pro­pri­ate time”, he fur­ther added. Dr. Ma­hesh Pa­tel, Chief Sci­en­tific Of­fi­cer of New Drug Dis­cov­ery, Wockhardt fur­ther added,

“Wockhardt’s drug dis­cov­ery pro­gram has im­mensely ben­e­fit­ted from global col­lab­o­ra­tions with uni­ver­si­ties and sci­en­tists of in­ter­na­tional re­pute in the ar­eas of pub­lic health, In­fec­tious dis­eases and clin­i­cal mi­cro­bi­ol­ogy”. “Wockhardt con­ducted ex­ten­sive stud­ies for iden­ti­fy­ing a re­gion in the Mid­dle East to es­tab­lish a strong man­u­fac­tur­ing pres­ence for its ad­vanced patented drugs. JAFZA was found to be ap­pro­pri­ate for the fac­tory premises for man­u­fac­tur­ing patented pro­pri­etary drugs for global mar­kets”, added Dr. Ha­bil Kho­raki­wala. Wockhardt Bio AG man­u­fac­tur­ing fa­cil­ity is de­signed to meet stan­dards of var­i­ous in­ter­na­tional reg­u­la­tory agen­cies and the stan­dards as set by the Lo­cal Min­istry of Health. The fa­cil­ity meets the needs of Asep­tic Dry Pow­der In­ject able man­u­fac­tur­ing and fill­ing with a high qual­ity op­er­a­tion. This fa­cil­ity is ded­i­cated to launch its novel New Chem­i­cal En­ti­ties in the An­tibi­otics seg­ment to the world from UAE. The fa­cil­ity is spread over 10,000 sq. me­ters of space, self-suf­fi­cient for han­dling Ware­hous­ing, Man­u­fac­tur­ing Op­er­a­tions, Prod­uct Test­ing and Prod­uct Sta­bil­ity. The fa­cil­ity is equipped with bestin-class and fully au­to­mated man­u­fac­tur­ing equip­ments and clean util­ity sys­tems. The de­sign takes into ac­count the re­quire­ments for Prod­uct & Per­son­nel Safety and Prod­uct Qual­ity with com­plete close trans­fers and high lev­els of steril­ity as­sur­ances. About Wockhardt: Wockhardt is a global phar­ma­ceu­ti­cal and biotech­nol­ogy or­gan­i­sa­tion, pro­vid­ing af­ford­able, high-qual­ity medicines for a health­ier world. It is In­dia’s lead­ing re­search-based global health­care en­ter­prise with rel­e­vance in the fields of Phar­ma­ceu­ti­cals, Biotech­nol­ogy and a chain of ad­vanced Su­per Spe­cial­ity Hos­pi­tals. Wockhardt is a true In­dian Multi­Na­tional Com­pany with a mul­ti­eth­nic work­force of 8600 Wockhardt As­so­ciates from 21 dif­fer­ent na­tion­al­i­ties glob­ally. It has 3 re­search cen­tres and 12 man­u­fac­tur­ing plants, with busi­nesses rang­ing from the man­u­fac­ture and mar­ket­ing of Phar­ma­ceu­ti­cal and Bio­phar­ma­ceu­ti­cal for­mu­la­tions, Ac­tive Phar­ma­ceu­ti­cal In­gre­di­ents (APIs) and Vac­cines. New Wockhardt. New way of think­ing Wockhardt is a busi­ness in tran­si­tion. New and in­no­va­tive busi­ness mod­els are in mo­tion to make the most of emerg­ing op­por­tu­ni­ties. A new drive for growth to­day per­me­ates every mind-set, process and tech­noin­no­va­tion within Wockhardt. At Wockhardt, we are look­ing at new ways of think­ing, new ways of work­ing and new ways to touch peo­ple’s lives. Build­ing a new Wockhardt Wockhardt’s Founder Chair­man and Group CEO, Dr. Ha­bil Kho­raki­wala says, “A decade ago, I saw a chang­ing world that I be­lieved would present us with large-scale fu­ture op­por­tu­ni­ties in the field of phar­ma­ceu­ti­cals and biotech­nol­ogy. We steered our busi­ness model to lever­age our re­search ca­pa­bil­i­ties in pro­vid­ing in­no­va­tive so­lu­tions and by con­stantly up­grad­ing our world-class man­u­fac­tur­ing fa­cil­i­ties. We ven­tured out­side In­dia sys­tem­at­i­cally and po­si­tioned our­selves mainly in the Euro­pean and the US mar­kets, which cur­rently gen­er­ates over 76% of our rev­enues.” Grow­ing pres­ence around the world Head-quatered in Mum­bai, In­dia, Wockhardt has full-fledged op­er­a­tions in the USA, UK, Ire­land and France. It also has its mar­ket­ing pres­ence in emerg­ing mar­kets of Rus­sia, Brazil, Mex­ico, Viet­nam, Philip­pines, Nige­ria, Kenya, Ghana, Tan­za­nia, Uganda, Nepal, Myan­mar, Sri Lanka, Mau­ri­tius, Le­banon and Kuwait. Spear­head­ing Re­search & Devel­op­ment Wockhardt’s core busi­ness is in­no­va­tion. It uses science and tech­nol­ogy to de­velop medicines and other prod­ucts that im­prove the qual­ity of mil­lions peo­ple’s lives through bet­ter health. Wockhardt has proved its tech­ni­cal ex­cel­lence by de­vel­op­ing patented mod­i­fied re­lease for­mu­la­tions and re­com­bi­nant biotech­nol­ogy prod­ucts. It has a multi-dis­ci­plinary R&D pro­gramme with more than 607 sci­en­tists, in­clud­ing over 80 doc­tor­ates, in the ar­eas of:

Phar­ma­ceu­ti­cal Re­search Biotech­nol­ogy & Ge­nomics


Novel Drug De­liv­ery Sys­tems

New Drug Dis­cov­ery

Pro­gramme. API Re­search

In­tel­lec­tual Prop­erty Wockhardt is in the fore­front of In­tel­lec­tual Prop­erty cre­ation with 1,733 patents filed till date, of which 228 patents have been granted. Our ca­pa­bil­ity and com­mit­ment in pur­su­ing In­tel­lec­tual Prop­erty has been recog­nised by the Govern­ment of In­dia for four years in a row, with an award for the max­i­mum num­ber of ‘Patent fil­ings and Grants from In­dia’. Wockhardt is de­ter­mined to cre­ate bench­marks for a promis­ing fu­ture.

Dr. Ha­bil Kho­raki­wala, Founder Chair­man of Wockhardt

Dr. Mur­taza Kho­raki­wala, Man­ag­ing Di­rec­tor of Wockhardt

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.